Stockscreener 앱 받기
18.80
1.37%
0.25
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Syndax Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
Syndax Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Eventide Asset Management LLC Has $26.01 Million Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial DataWhat's Changed - Yahoo Finance
Voss Capital LP Buys Shares of 125,000 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Rhenman & Partners Asset Management AB Sells 87,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options - Stock Titan
SNDX (NASDAQ) Rule 144 notice: Director-linked sale of 31,235 shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
SNDX Stock Price, Quote & Chart - ChartMill
[144] Syndax Pharmaceuticals Inc SEC Filing - Stock Titan
Syndax showcases revuforj (revumenib) data at EHA 2026 - grafa.com
Syndax (SNDX) Reveals Encouraging Results from SAVE Trial for AM - GuruFocus
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced (NASDAQ:SNDX) - Seeking Alpha
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 - The Manila Times
Leukemia drug revumenib shows up to 97% remission in EHA 2026 data - Stock Titan
Syndax Pharmaceuticals Announces Publication of Save Data on Revuforj in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML - marketscreener.com
SNDX6417984 Bond Coupon Analysis — Rate & Payments - TradingView
Syndax Pharmaceuticals (NASDAQ: SNDX) issues $250M 2.25% convertible notes due 2031 - Stock Titan
Syndax (NASDAQ: SNDX) investors back 2026 equity plan and new ESPP - Stock Titan
Syndax Pharmaceuticals, Inc. Bonds — Corporate Bond Rates - TradingView
Syndax Pharmaceuticals Inc Bonds — Corporate Bond Rates - TradingView
Syndax Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:SNDX) - MarketBeat
SNDX6417984 Bond Analysis — Key Metrics - TradingView
Transcript : Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 02 - marketscreener.com
SNDX: Revuforj's clinical success and expanding pipeline drive growth, with new capital fueling future innovation - TradingView
Syndax Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
SNDX6417984 Bond Price and Chart — FINRA:SNDX6417984 - TradingView
Price-Driven Insight from (SNDX) for Rule-Based Strategy - Stock Traders Daily
A Look At Syndax Pharmaceuticals (SNDX) Valuation After Recent Share Price Weakness - Sahm
Syndax Pharmaceuticals prices $250M senior convertible notes - MSN
Syndax Pharmaceuticals prices $250 million convertible notes By Investing.com - Investing.com Australia
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax (SNDX) Launches $250M Convertible Senior Note Offering - GuruFocus
Syndax Pharmaceuticals (SNDX) Faces Selling Pressure, Testing Near-Term Support LevelsLiquidity Order Flow - newsline.com
Syndax Pharmaceuticals prices $250 million convertible notes - Investing.com UK
Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Syndax Pharmaceuticals Prices $250 Million Convertible Senior Notes - TipRanks
Syndax Prices $250 Million 2.25% Convertible Notes Due 2031 in Private Placement - TradingView
Syndax (NASDAQ: SNDX) raises $250M via 2.25% convertible notes due 2031 - Stock Titan
Syndax Pharmaceuticals Announces $250 Million Private Placement of Convertible Senior Notes - Quiver Quantitative
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes - The Manila Times
Syndax lines up $250M in 2.25% debt swappable into its stock - Stock Titan
H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating on ASCO data - Investing.com Canada
Stifel reiterates Syndax Pharmaceuticals stock rating on ASCO data By Investing.com - Investing.com Canada
Syndax (SNDX) CFO sells 1,177 shares to cover RSU tax withholding - Stock Titan
Syndax Pharmaceuticals (SNDX) CEO sells shares to cover tax obligations - Stock Titan
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data - The Manila Times
Small leukemia study finds 90% 2-year survival with revumenib after transplant - Stock Titan
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026 - The Manila Times
Inside Syndax’s next cancer R&D day: leukemia and lung disease trials - Stock Titan
Syndax Pharmaceuticals (SNDX) Edges Lower Amid Mixed Sentiment — Key Levels in FocusPut Flow Alert - The Legal Advocate
SNDX: Compelling clinical results and commercial momentum position both franchises for significant growth - TradingView
1.79%
0.89%
자본화:
|
볼륨(24시간):